KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.1 billion.

  • Vertex Pharmaceuticals' Income towards Parent Company rose 358.71% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 86596.5%. This contributed to the annual value of -$535.6 million for FY2024, which is 11479.72% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Income towards Parent Company of $1.1 billion as of Q3 2025, which was up 358.71% from $1.0 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Income towards Parent Company high stood at $1.1 billion for Q1 2024, and its period low was -$3.6 billion during Q2 2024.
  • Its 5-year average for Income towards Parent Company is $605.8 million, with a median of $851.9 million in 2021.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Income towards Parent Company soared by 110970.15% in 2022, and later tumbled by 49244.29% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Income towards Parent Company (Quarter) stood at $770.1 million in 2021, then grew by 6.34% to $818.9 million in 2022, then grew by 18.31% to $968.8 million in 2023, then dropped by 5.76% to $913.0 million in 2024, then grew by 18.61% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.0 billion for Q2 2025, and $646.3 million during Q1 2025.